Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Partnerships Target Drug Conjugates

by Ann M. Thayer
June 30, 2014 | A version of this story appeared in Volume 92, Issue 26

Sorrento Therapeutics and Morphotek, a subsidiary of Japan’s Eisai, will collaborate on generating antibody-drug conjugates (ADCs) for cancer. Morphotek antibodies will be combined with chemotherapeutic agents using Sorrento conjugation chemistry and linkers. Sorrento could receive up to $50 million. Similarly, Mersana Therapeutics will work with Merck Serono to develop ADCs for oncology targets. The partners will use Mersana’s biodegradable polymer linker, or Fleximer technology, to generate a range of ADCs from several cytotoxic agents conjugated to Merck antibodies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.